EMMA · XBRL financial data

Emmaus Life Sciences financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EMMA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	23,167	20,610	18,390	29,597	16,653	12,453
Cost of revenue	2,248	3,312	2,588	1,342	1,201	857
Gross profit	20,919	17,298	15,802	28,255	15,452	11,596
Research and development	2,408	4,110	1,725	1,189	657	313
General and administrative	13,678	13,438	13,170	14,891	10,687	8,179
Total operating expenses	20,951	23,426	22,388	24,715	17,346	11,365
Operating income (loss)	(32)	(6,128)	(6,586)	3,540	(1,894)	231
Interest expense	5,989	3,101	5,013	7,383	5,492	7,134
Income tax expense (benefit)	(381)	25	60	(59)	29	9
Net income (loss)	1,354	(15,946)	(10,625)	(3,733)	(6,453)	(7,492)
Earnings per share, basic USD per share	—	(0.32)	(0.21)	(0.07)	(0.10)	(0.12)
Earnings per share, diluted USD per share	—	(0.32)	(0.21)	(0.07)	(0.10)	(0.12)
Weighted average shares, basic thousands of shares	48,897	49,253	49,440	53,105	63,235	64,039
Weighted average shares, diluted thousands of shares	—	49,253	49,440	53,105	63,235	64,039

Fiscal years (EMMA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,487	2,279	2,021	2,547	1,389	2,127
Accounts receivable	198	1,040	375	5,524	2,623	2,804
Inventory	7,087	4,392	2,379	1,711	1,635	1,555
Prepaid and other current assets	1,485	1,380	1,514	1,727	1,120	1,260
Total current assets	11,257	9,091	6,289	11,509	6,767	7,746
Property and equipment, net	120	147	75	59	46	113
Right-of-use asset	4,072	3,485	2,799	2,337	1,530	766
Total assets	59,536	56,734	48,225	35,179	23,602	21,436
Accounts payable	2,023	2,583	3,785	5,887	5,175	5,979
Accrued liabilities	4,769	5,936	7,239	8,174	7,732	9,321
Total current liabilities	23,382	37,100	54,323	61,507	63,555	69,072
Lease liability, non-current	3,470	3,261	2,553	1,839	815	1,409
Total liabilities	64,694	78,184	82,316	82,935	80,081	85,044
Accumulated deficit	(225,079)	(241,266)	(252,337)	(256,122)	(262,575)	(270,067)
Total stockholders' equity	(5,158)	(21,450)	(34,091)	(47,756)	(56,479)	(63,608)
Total liabilities and equity	59,536	56,734	48,225	35,179	23,602	21,436
Common shares outstanding (cover page) thousands of shares	49,312	49,312	50,935	61,846	63,866	70,188

Fiscal years (EMMA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,354	(15,946)	(10,625)	(3,733)	(6,453)	(7,492)
Stock-based compensation	739	553	16	1,262	256	25
Depreciation and amortization	60	59	53	32	22	39
Net cash from operating activities	(2,451)	(1,254)	(5,073)	(1,503)	(2,286)	(11)
Purchases of property and equipment	15	73	26	17	12	1
Net cash from investing activities	5,470	(6,377)	(2,387)	(432)	2,500	2,171
Proceeds from issuing common stock	142	—	—	—	—	—
Net cash from financing activities	(2,310)	7,411	7,233	2,477	(1,353)	(1,425)
Net change in cash	718	(208)	(258)	526	(1,158)	738

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
Avenue Therapeutics	1,942	0	(475)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
International Stem Cell	1,089	2,675	167*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Cyanotech	649	6,976	108*	7.4M	—	Q2 FY25 10-QSep 30, 2025
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Mosaic ImmunoEngineering	0	not reported	(0)*	7.2M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Evoke Pharma	11,576	4,284	(522)*	1.7M	22.2 quarters	Q3 FY25 10-QSep 30, 2025
China Foods Holdings	16	0	(94)*	20.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Hepion Pharmaceuticals	1,629	not reported	(1,394)*	90.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.